How to register for Falk Forum 76

To register for this Falk Forum please visit the Dr Falk Pharma website at:
www.drfalk.co.uk/meeting/falk-forum-76

Please complete all required fields in the registration form including any dietary requirements and ensure you click the "submit" button. You will receive an email confirming your registration within 24 hours.

Important: If you do not receive the confirmation email please contact Dr Falk on:
office@drfalkpharma.co.uk

Please Note: if you have not yet registered for the Dr Falk website you will first need to register by going to www.drfalk.co.uk and clicking on the HCP tab. Following registration for the website please use the meeting link above to register for this Falk Forum.

University Hospitals Birmingham
NHS Foundation Trust

For any queries regarding your registration please contact Dr Falk Pharma on
office@drfalkpharma.co.uk or 01628 536600.
Dear Colleague,

Autoimmune liver diseases (AILD) represent the greatest unmet need in modern hepatology, given their indeterminate aetiology, heterogeneous clinical presentations, and variable rates of clinical progression. Whilst all are considered rare diseases in their own right, AILD represent a leading indication for transplantation across the UK and Europe. Therapeutic options in autoimmune hepatitis whilst effective are imprecise and accompanied by significant impact on patient quality of life. Primary biliary cholangitis, the commonest of all three diseases, can be treated effectively with timely access to bile acid therapy; however, underdosing is common, and therapeutic shortfall evident in up to a third of patients. Primary sclerosing cholangitis is perhaps the greatest challenge in clinical practice, for which liver transplantation remains the only life-saving intervention.

In selecting the topic of this special forum, we present a contemporary overview of evidence-based clinical practice and research activity in AILD. Each speaker is a key opinion leader in their field, with coverage of topics that encompass risk stratification, timing and choice of therapeutic strategies, clinical trial updates, and management considerations in special populations.

Kind Regards

Dr Palak Trivedi

Location:
The MacDonald Burlington Hotel,
Burlington Arcade,
126 New Street,
Birmingham,
B2 4JQ

Agenda

**Autoimmune Liver Disease – Dr Palak Trivedi (Birmingham)**

08.15 – 09.00  Registration
09.00 – 09.05  Introduction and Welcome - Dr Palak Trivedi (Birmingham)
09.05 – 09.25  The need for high-quality evidence in autoimmune liver disease: reading between the (guidelines - Dr Ian Rowe (Leeds)

**PBC in 2020 – Chair: Dr Ye Oo (Birmingham)**

09.25 – 09.30  The PBC Foundation - Mr Robert Mitchell-Thain (PBC Foundation)
09.30 – 09.50  From risk stratification to second-line therapy  
Dr George Mells (Cambridge)
09.50 – 10.10  Pruritus in cholestasis, from current to future therapeutic options  
Dr Vinod Hegade (Leeds)
10.10 – 10.30  Overlap syndromes: Case Presentations - Rosemary Faulkes (Birmingham), Nadir Abbas (Birmingham) & Dr Palak Trivedi (Birmingham)
10.30 – 10.45  Panel Discussion
10.45 – 11.05  Coffee Break

**Autoimmune Hepatitis; its easy isn’t it? – Chair: Dr Dermot Gleeson (Sheffield)**

11.05 – 11.10  AIH Support - Ms Ann Brownlee (AIH Support)
11.10 – 11.30  What is the ideal therapeutic endpoint in AIH and how do we get there?  
Dr Dermot Gleeson (Sheffield)
11.30 – 11.50  Second-line therapy in AIH and the variation in care delivery across the UK: how did we get here? - Dr Jessica Dyson (Newcastle)
11.50 – 12.10  Autoimmune and ‘chronic’ cholestatic liver disease in pregnancy  
Dr Rachel Westbrook (London)
12.10 – 12.25  Panel Discussion
12.25 – 13.10  Lunch Break

**Therapeutic paradigm in AILD – Chair: Dr Roger Chapman (Oxford)**

13.10 – 13.15  PSC Support - Ms Martine Walmsley (PSC Support)
13.15 – 13.40  Bile acid therapy for autoimmune liver disease  
Dr Emina Halilbasic (Austria)
13.40 – 14.00  Cell and Immunomodulatory therapy in autoimmune liver disease  
Professor David Adams (Birmingham)
14.00 – 14.20  Endoscopic management of PSC - Professor Douglas Thorburn (London)
14.20 – 14.40  Liver transplantation in autoimmune liver disease: the before and after  
Dr James Ferguson (Birmingham)
14.40 – 14.55  Panel Discussion
14.55 – 15.15  Coffee Break

**Special considerations for special populations – Chair: Dr Emina Halilbasic (Austria)**

15.15 – 15.35  The allied health professionals’ perspective  
Ms Jennifer Hayden (Birmingham) & Ms Alice Vallance (Birmingham)
15.35 – 15.55  The convenient and inconvenient truths of primary sclerosing cholangitis (PSC) - Dr Palak Trivedi (Birmingham)
15.55 – 16.15  IgG4 – Related hepatobiliary disease - Dr Emma Culver (Oxford)
16.15 – 16.25  Panel Discussion
16.25 – 16.30  Closing remarks - Dr Palak Trivedi (Birmingham)